Stock Scorecard



Stock Summary for BridgeBio Pharma Inc (BBIO) - $51.32 as of 8/18/2025 12:15:03 PM EST

Total Score

4 out of 30

Safety Score

46 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BBIO

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BBIO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BBIO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BBIO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BBIO (46 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BBIO

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition - Helix Acquisition Corp ( NASDAQ:HLXB ) 8/11/2025 8:30:00 PM
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition 8/11/2025 8:30:00 PM
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics 8/6/2025 11:33:00 AM
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - BridgeBio Pharma ( NASDAQ:BBIO ) , Helix Acquisition Corp ( NASDAQ:HLXB ) 8/6/2025 11:33:00 AM
BridgeBio Pharma ( BBIO ) Reports Q2 Loss, Beats Revenue Estimates 8/5/2025 9:25:00 PM
Check Out What Whales Are Doing With BBIO - BridgeBio Pharma ( NASDAQ:BBIO ) 8/5/2025 8:01:00 PM
Analysts Estimate Amphastar Pharmaceuticals ( AMPH ) to Report a Decline in Earnings: What to Look Out for 7/31/2025 2:00:00 PM
BridgeBio Pharma ( BBIO ) Expected to Beat Earnings Estimates: Should You Buy? 7/29/2025 2:00:00 PM
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 7/23/2025 11:30:00 AM
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination - BridgeBio Pharma ( NASDAQ:BBIO ) , Helix Acquisition Corp ( NASDAQ:HLXB ) 7/11/2025 11:43:00 AM

Financial Details for BBIO

Company Overview

Ticker BBIO
Company Name BridgeBio Pharma Inc
Country USA
Description BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2025
Next Earnings Date 10/30/2025

Stock Price History

Last Day Price 51.32
Price 4 Years Ago 16.68
Last Day Price Updated 8/18/2025 12:15:03 PM EST
Last Day Volume 2,221,530
Average Daily Volume 2,813,808
52-Week High 51.86
52-Week Low 21.72
Last Price to 52 Week Low 136.28%

Valuation Measures

Trailing PE N/A
Industry PE 43.35
Sector PE 59.06
5-Year Average PE -9.79
Free Cash Flow Ratio 13.09
Industry Free Cash Flow Ratio 15.81
Sector Free Cash Flow Ratio 30.26
Current Ratio Most Recent Quarter 5.19
Total Cash Per Share 3.92
Book Value Per Share Most Recent Quarter -9.35
Price to Book Ratio 123.68
Industry Price to Book Ratio 31.11
Sector Price to Book Ratio 26.93
Price to Sales Ratio Twelve Trailing Months 41.49
Industry Price to Sales Ratio Twelve Trailing Months 34.46
Sector Price to Sales Ratio Twelve Trailing Months 15.21
Analyst Buy Ratings 15
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 191,169,000
Market Capitalization 9,810,793,080
Institutional Ownership 98.32%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 16.70%
Reported EPS 12 Trailing Months -4.13
Reported EPS Past Year -1.94
Reported EPS Prior Year -2.82
Net Income Twelve Trailing Months -776,415,000
Net Income Past Year -535,762,000
Net Income Prior Year -643,202,000
Quarterly Revenue Growth YOY 5,000.00%
5-Year Revenue Growth 40.48%
Operating Margin Twelve Trailing Months -120.70%

Balance Sheet

Total Cash Most Recent Quarter 749,402,000
Total Cash Past Year 681,101,000
Total Cash Prior Year 375,935,000
Net Cash Position Most Recent Quarter -1,100,157,000
Net Cash Position Past Year -1,040,281,000
Long Term Debt Past Year 1,721,382,000
Long Term Debt Prior Year 1,726,729,000
Total Debt Most Recent Quarter 1,849,559,000
Equity to Debt Ratio Past Year -5.53
Equity to Debt Ratio Most Recent Quarter -28.98
Total Stockholder Equity Past Year -1,457,612,000
Total Stockholder Equity Prior Year -1,354,257,000
Total Stockholder Equity Most Recent Quarter -1,787,860,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -667,466,000
Free Cash Flow Per Share Twelve Trailing Months -3.49
Free Cash Flow Past Year -521,659,000
Free Cash Flow Prior Year -529,026,000

Options

Put/Call Ratio 0.54
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.15
MACD Signal 0.98
20-Day Bollinger Lower Band 28.28
20-Day Bollinger Middle Band 40.15
20-Day Bollinger Upper Band 52.02
Beta 1.23
RSI 67.52
50-Day SMA 33.38
150-Day SMA 26.20
200-Day SMA 23.84

System

Modified 8/15/2025 6:28:39 PM EST